Encompass Health Beats Q2 Estimates, Raises Full-Year Outlook
EHC sits 19% above its 52-week low of $92.77.
Summary
Encompass Health delivered a strong Q2, with revenue up 9.6% to $1.6B and adjusted EPS of $1.55 beating the $1.48 consensus. The company raised full-year guidance across the board—net operating revenue now seen at $6.41B-$6.49B, adjusted EBITDA at $1.365B-$1.395B, and adjusted EPS at $6.02-$6.25. Volume growth was solid, with discharges up 5.6% and same-store growth of 2.8%, while revenue per discharge rose 3.9%. The board also expanded the buyback authorization to $1B, signaling confidence. This follows a $500M debt offering in May, which likely supports ongoing hospital expansion—three new hospitals and 54 beds added in H1. The raised guidance and buyback expansion are material positive signals for a $11B market cap company.
At the time of this announcement, EHC was trading at $110.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $92.77 to $127.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.